The Application of Rapid Fresh Digital Pathology on the Diagnosis and Biomarker Testing of Lung Cancer

Launched by NATIONAL TAIWAN UNIVERSITY HOSPITAL · Jul 4, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new method to help doctors diagnose lung cancer more quickly and accurately during surgery. The researchers are developing a process that uses advanced technology to stain lung tissue samples right after they are removed from the body. This will allow doctors to see the cancer more clearly and make better decisions about how much tissue to remove while keeping as much healthy tissue as possible. The goal is to improve the quality of care for patients with lung cancer.

To participate in this trial, you need to be an adult aged 20 or older and have been diagnosed with lung cancer or lung tumors that require surgery. The study plans to include 300 patients. If you join, you can expect to have your lung tissue analyzed using this new technology during your surgery, which may help doctors provide a more accurate diagnosis and treatment plan. However, if you are unable to give consent or if your condition does not allow for a clear diagnosis, you may not be eligible for this study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • (1) Adults aged 20 and above.
• • (2) Patients diagnosed with lung cancer or lung tumors, scheduled for surgical resection.
• • A total of 300 patients are expected to be included.
• Exclusion Criteria:
• • (1) Patients unable to provide consent. (e.g., inability to speak, inability to communicate in Chinese, etc.).
• • (2) Patients for whom a definitive pathological diagnosis cannot be established.
• • (3) Patients suitable only for biopsy and not for surgical resection.
• • (4) Exclude specimens that are too small or lesions that are too small to retain extra tissue.